DAFTAR PUSTAKA

1. Monroy-Sosa A., Chakravarthi S.S., Garza-Salazar J.G., Garcia A.M., Kassam A.B. 2021. Principles of Neuro-Oncology. Switzerland : Springer
2. Buerki R. A., Horbinski C. M., Kruser T., Horowitz P. M., James C. D., Lukas, R. V. 2018. An overview of meningiomas. Future Oncol. 14(21), 2161–2177 – DOI: 10.2217/fon-2018-0006
3. Central Brain Tumor Registry of the United States (CBTRUS), 2005. Primary brain tumors in the United States statistical report 1998–2002. www.cbtrus.org/reports/2005-2006/2006report.pdf
4. Richard, W. H. 2017. Youmans and Winn Neurological Surgery. 7th Ed. Philadelphia, PA : Elsevier
5. Widodo D., Ihwan A., Arungpadang MP. 2020. Evaluasi kasus meningioma di Rumah Sakit Wahidin Sudirohusodo Makassar tahun 2012-2018. Intisari Sains Medis. DOI: 10.15562/ism.v11i3.767
6. Damayanti AA., Kalanjati VP., Wahyuhadi J. 2021. Korelasi Usia dan Jenis Kelamin dengan Angka Kejadian Meningioma. Jurnal Aksona. Vol 1 Nomor 1, Januari 2021: 34–38
7. Sunantara IG., Sriwidyani NP., Ekawati NP., Saputra H. 2021. Gambarran klinikopatologi pasien meningioma dari taun 2014-2018 di RSUP Sanglah Denpasar. Jurnal Medika Udayana. DOI:10.24843.MU.2021.V10.i3.P12
8. Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K. 2016. WHO Classification of Tumours of the Central Nervous System. Revised 4th Ed. Lyon : International Agency for Research on Cancer (IARC)
9. Kementerian Kesehatan R.I. 2017. Pedoman Nasional Pelayanan Kedokteran (PNPK) Tumor Otak : Jakarta
10. Al-Mefty, O., DeMonte, F., McDermott, M. W. 2011. Al-Mefty's Meningiomas. 2nd Ed. New York : Thieme
11. Moliterno, J., Omuro, A. 2020. Meningiomas-Comprehensive Strategies for Management. Switzerland : Springer
12. Ng HK, Poon WS, Goh K, Chan MS. 1996. Histopathology of post-embolized meningiomas. Am J Surg Pathol. DOI: 10.1097/00000478-199610000-00008

13. Brokinkel B, Hess K, Mawrin C. 2017. Brain invasion in meningiomas-clinical considerations and impact of neuropathological evaluation: a systematic review. Neuro-Oncology. DOI: 10.1093/neuonc/nox071
14. Perry A, Stafford SL, Scheithauer BW, Suman VJ, Lohse CM. 1997. Meningioma grading: an analysis of histologic parameters. Am J Surg Pathol. DOI: 10.1097/00000478-199712000-00008
15. Tauziede-Espariat A, Parfait B, Besnard A, et al. 2018. Loss of SMARCE1 expression is a specific diagnostic marker of clear cell meningioma: a comprehensive immunophenotypical and molecular analysis. Brain Pathol. DOI: 10.1111/bpa.12524
16. Perry A, Scheithauer BW, Stafford SL, Lohse CM, Wollan PC. 1999. “Malignancy” in meningiomas: a clinicopathologic study of 116 patients, with grading implications. Cancer. DOI: 10.1002/(sici)1097-0142(19990501)85:9<2046::aid-cncr23>3.0.co;2-m
17. Perry A, Scheithauer BW, Stafford SL, Abell-Aleff PC, Meyer FB. 1998. “Rhabdoid” meningioma: an aggressive variant. Am J Surg Pathol. DOI: 10.1097/00000478-199812000-00005
18. Sun C. Dou Z. Wu J. et al. 2020. The Preferred Locations of Meningioma According to Different Biological Characteristics Based on Voxel-Wise Analysis. Front. Oncol. DOI: 10.3389/fonc.2020.01412
19. Gunadi SV. Suryanti S. Yohana R. 2018. The Distribution of Meningioma in Dr. Hasan Sadikin General Hospital Bandung Period 2010–2013. Althea Medical Journal. DOI: https://doi.org/10.15850/amj.v5n3.1062
20. Batchelor, T., Nishikawa, R., Tarbell, N., Weller, M. 2017. Oxford Textbook of Neuro-Oncology. New York : Oxford University Press
21. Zakhari N., Torres C, Castillo M., Nguyen T. B. 2017. Uncommon Cranial Meningioma: Key Imaging Features on Conventional and Advanced Imaging. Clin Neuroradiol. Springer-Verlag Berlin Heidelberg - DOI 10.1007/s00062-017-0583-y
22. Khu KJ, Ng I, Ng WH. 2009. The relationship between parasagittal and falcine meningiomas and the superficial cortical veins: a virtual reality study. Acta Neurochir. DOI: 10.1007/s00701-009-0379-1
23. Tonn, J. C., Rutka, J. T., Reardon, D. A., Westphal, M. 2019. Oncology of CNS Tumors. 3rd Ed. Switzerland : Springer

24. Pavelin S, Becic K, Forempoher G, Mrklic I, Pogorelic Z, Titlic M, Andelinovic S. 2013. Expression of Ki-67 and p53 in meningiomas. Neoplasma. DOI: 10.4149/neo_2013_062
25. Babu S, Uppin SG, Uppin MS, Panigrahi MK, Saradhi V, Bhattacharjee S, Sahu BP, Purohit AK, Challa S. 2011. Meningiomas: correlation of Ki67 with histological grade. Neurol India. DOI: 10.4103/0028-3886.79140
26. Lanzafame S, Torrisi A, Barbagallo G, Emmanuele C, Alberio N, Albanese V. 2000. Correlation between histological grade, MIB-1, p53, and recurrence in 69 completely resected primary intracranial meningiomas with a 6 year mean follow-up. Pathol Res Practice. DOI: 10.1016/S0344-0338(00)80050-3
27. Pfisterer WK, Coons SW, Aboul-Enein F, Hendricks WP, Scheck AC, Preul MC. 2008. Implicating chromosomal aberrations with meningioma growth and recurrence: results from FISH and MIB-I analysis of grades I and II meningioma tissue. J Neuro-Oncol. DOI: 10.1007/s11060-007-9498-9
28. Li J., Liang R., Song C., Xiang Y., Liu Y. 2019. Prognostic Value of Ki-67/MIB-1 Expression in Meningioma Patients: A Meta-Analysis. DOI:10.1615/CritRevEukaryotGeneExpr.2019025430
29. Scholzen T., Gerdes J., 2000. The Ki-67 Protein: From the Known and the Unknown. Journal Of Cellular Physiology 182:311–322. DOI:10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9
30. Li L.T., Jiang G., Chen Q., Zheng J.N. 2014. Ki67 is a promising molecular target in the diagnosis of cancer. Molecular Medicine Reports 11: 1566-1572. DOI: 10.3892/mmr.2014.2914
31. Barnum K.J., O'Connell M.J. 2014. Cell Cycle Regulation by Checkpoints. DOI: 10.1007/978-1-4939-0888-2_2
32. Yerushalmi R., Woods R., Ravdin P.M., Hayes M.M., Gelmon K.A. 2010. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol (11) 174–83. DOI: 10.1016/S1470-2045(09)70262-1
33. Gerdes J., Lemke H., Baisch H., et al. 1984. Cell cycle analysis of a cell proliferationassociated human nuclear antigen defined by the monoclonal antibody Ki-67, J. Immunol. 133 (4) 1710–1715. PMID: 6206131
34. Jonat W., Arnold N. 2011. Is the Ki-67 labelling index ready for clinical use? Ann. Oncol. (22) 500–502. DOI: 10.1093/annonc/mdq732

35. Endl E., Gerdes J. 2000. Posttranslational modifications of the KI-67 protein coincide with two major checkpoints during mitosis, J. Cell. Physiol. 182 (3) 371–380. DOI:10.1002/(SICI)1097-4652(200003)182:3<371::AID-JCP8>3.0.CO;2-J
36. Vanneste D., Takagi M., Imamoto N., et al. 2009. The role of Hklp2 in the stabilization and maintenance of spindle bipolarity, Curr. Biol. 19 (20) 1712–1717. DOI: 10.1016/j.cub.2009.09.019
37. Takagi M., Sueishi M., Saiwaki T., et al. 2001. A novel nucleolar protein, NIFK, interacts with the forkhead associated domain of Ki-67 antigen in mitosis, J. Biol. Chem. 276 (27) 25386–25391. DOI: 10.1074/jbc.M102227200
38. Ye XS., Xu G., Pu RT., et al. 1995. The NIMA protein kinase is hyperphosphorylated and activated downstream of p34cdc2/cyclin B: coordination of two mitosis promoting kinases, EMBO J. 14 (5) 986–994. PMCID: PMC398170
39. Che S., Weil M.M., Nelman-Gonzalez M, et al. 1997. MPM-2 epitope sequence is not sufficient for recognition and phosphorylation by ME kinase-H, FEBS Lett. 413 (3) 417–423. DOI: 10.1016/s0014-5793(97)00948-4
40. Mueller P.R., Coleman T.R., Dunphy W.G. 1995. Cell cycle regulation of a Xenopus Wee1- like kinase, Mol. Biol. Cell 6 (1) 119–134. DOI: 10.1091/mbc.6.1.119
41. Kuang J., Ashorn C.L., Gonzalez-Kuyvenhoven M. 1994. CDC25 is one of the MPM-2 antigens involved in the activation of maturation-promoting factor, Mol. Biol. Cell 5 (2) 135–145. DOI: 10.1091/mbc.5.2.135
42. Taagepera S., Rao P.N., Drake F.H., et al. 1993. DNA topoisomerase II alpha is the major chromosome protein recognized by the mitotic phosphoprotein antibody MPM-2, Proc. Natl. Acad. Sci. 90 (18) 8407–8411. DOI: 10.1073/pnas.90.18.8407
43. King R.W., Peters J.M., Tugendreich S., et al. 1995. A 20S complex containing CDC27 and CDC16 catalyzes the mitosis-specific conjugation of ubiquitin to cyclin B, Cell 81 (2) 279–288. DOI: 10.1016/0092-8674(95)90338-0

44. Satyanarayana A., Kaldis P. 2009. Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms, Oncogene 28 (33) 2925–2939. DOI: https://doi.org/10.1038/onc.2009.170
45. Orjuela M., Orlow I., Dudas M., et al. 2001. Alterations of cell cycle regulators affecting the RB pathway in nonfamilial retinoblastoma, Hum. Pathol. 32 (5) 537–544. DOI: 10.1053/hupa.2001.24325
46. Ali H.R., Dawson S.J., Blows F.M., et al. 2012. A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER-positive breast cancer, J. Pathol. 226 (1) 97–107. DOI: 10.1002/path.2976
47. Halm U, Tannapfel A, Breitung B, et al. 2000. Apoptosis and cell proliferation in the metaplasia-dysplasia-carcinoma-sequence of Barrett's esophagus. Hepatogastroenterology. PMID: 11020858
48. Rahmanzadeh R, Hüttmann G, Gerdes J and Sholzen T. 2007. Chromophore-assisted light inactivation of pKi67 leads to inhibition of ribosomal RNA synthesis. Cell Prolif. DOI: 10.1111/j.1365-2184.2007.00433.x
49. Panteva MT, Salari R, Bhattacharjee M, Chong LT. 2011. Direct observations of shifts in the β-sheet register of a protein-peptide complex using explicit solvent simulations. Biophys J. https://doi.org/10.1016/j.bpj.2011.03.035
50. Karamitopoulou E, Perentes E, Tolnay M, Probst A. 1998. Prognostic significance of MIB-1, p53, and bcl-2 immunoreactivity in meningiomas. Hum Pathol. DOI: 10.1016/s0046-8177(98)90224-6
51. Geyer FC, Rodrigues DN, Weigelt B, Reis-Filho JS. 2012. Molecular classification of estrogen receptor-positive/luminal breast cancers. Adv Anat Pathol. DOI: 10.1097/PAP.0b013e31823fafa0
52. Claudio PP, Zamparelli A, Garcia FU, et al. 2002. Expression of Cell-Cycle-regulated Proteins pRb2/p130, p107, p27kip1, p53, mdm-2, and Ki-67 (MIB-1) in Prostatic Gland Adenocarcinoma1. Clin Cancer. PMID: 12060621
53. Hu HY, Liu H, JW Zhang, et al. 2012. Clinical significance of Smac and Ki-67 expression in pancreatic cancer. Hepato-gastroenterology. DOI: 10.5754/hge12071

54. Kim BH, Bae YS, Kim SH, et al. 2012. Usefulness of Ki-67 (MIB-1) immunostaining in the diagnosis of pulmonary sclerosing hemangiomas. APMIS. DOI: 10.1111/j.1600-0463.2012.02945.x
55. De Aguiar PH, Aires R, Laws ER, et al. 2010. Labeling index in pituitary adenomas evaluated by means of MIB-1: is there a prognostic role? A critical review. Neurol Res. DOI: 10.1179/016164110X12670144737855
56. Prayson RA. 2005. The utility of MIB-1/Ki-67 immunostaining in the evaluation of central nervous system neoplasms. Adv Anat Pathol. DOI: 10.1097/01.pap.0000163957.21409.52
57. Lind-Landström T, Habberstad AH, Sundstrøm S, Torp SH. 2012. Prognostic value of histological features in diffuse astrocytomas WHO grade II. Int J Clin Exp Pathol. PMCID: PMC3294229
58. Nabi U, Nagi AH, Sami W. 2008. Ki-67 proliferating index and histological grade, type and stage of colorectal carcinoma. J Ayub Med Coll Abbottabad. PMID: 19999202
59. Hegazy A, Daoud SA, Ibrahim WS. 2014. Role of Ki-67, P53 and Bcl-2 in Advanced Colorectal Carcinoma. Academic Journal of Cancer Research. DOI: 10.5829/idosi.ajcr.2014.7.3.1111
60. Inwald EC, Klinkhammer-Schalke M, Hofstädter F. 2013. Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat. DOI: 10.1007/s10549-013-2560-8
61. Klöppel G, Perren A, Heiitz PU. 2004. The gastroenteropancreatic neuroendocrine cell system and its tumors. The WHO classification. Ann NY Acad Sci. DOI: 10.1196/annals.1294.002
62. Palmqvist R, Sellberg P, Oberg A, et al. 1999. Low tumour cell proliferation at the invasive marginis associated with a poor prognosis in Dukes' stage B colorectal cancers. Br. J. Cancer. DOI: 10.1038/sj.bjc.6690091
63. Kimura T, Tanaka S, Haruma K et al. 2000. Clinical significance of MUC1 and E-cadherin expression, cellular proliferation, and angiogenesis at the deepest invasive portion of colorectal cancer. Int J Oncol DOI: 10.3892/ijo.16.1.55
64. Martin B, Paesmans M, Mascaux C, et al. 2004. Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis. Br J Cancer. DOI: 10.1038/sj.bjc.6602233

65. Faes T, Pecceu A, Van Calenbergh S, Moerman P. 2012. Chorangiocarcinoma of the placenta: a case report and clinical review. Placenta. DOI: 10.1016/j.placenta.2012.04.012
66. Almeida JC, Menezes RP, Kuckelhaus SA, Bocca AL, Figueiredo F. 2007. Prognostic value of morphologic and clinical parameters in pT2 - pT3 prostate cancer. Int Braz J Urol. DOI: 10.1590/s1677-55382007000500007
67. Vaira V, Fedele G, Pyne S, et al. 2010. Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors. Proc Natl Acad Sci. DOI: https://doi.org/10.1073/pnas.0907676107
68. Hofman MS and Hicks RJ. 2012. Changing paradigms with molecular imaging of neuroendocrine tumors. Discov Med. PMID: 22846204
69. Laurinavicius A, Plancoulaine B, Laurinaviciene A, et al. 2014. A methodology to ensure and improve accuracy of Ki67 labelling index estimation by automated digital image analysis in breast cancer tissue, Breast Cancer Res. DOI: 10.1186/bcr3639
70. Zizi-Sermpetzoglou A, Moustou E, Petrakopoulou N, et al. 2012. Atypical polypoid adenomyoma of the uterus. A case report and a review of the literature. Eur J Gynaecol Oncol. PMID: 22439420
71. Ibrahim T, Farolfi A, Scarpi E, et al. 2013. Hormonal receptor, human epidermal growth factor receptor-2, and Ki67 discordance between primary breast cancer and paired metastases: Clinical impact. Oncology. DOI: 10.1159/000345795
72. Chlebowski RT, Col N, Winer EP, et al. 2002. American Society of Clinical Oncology Breast Cancer Technology Assessment Working Group: American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol. DOI: 10.1200/JCO.2002.06.029
73. Blancato J, Singh B, Liu A, Liao DJ, Dickson RB. 2004. Correlation of amplification and overexpression of the c-myc oncogene in high grade breast cancer: FISH, in situ hybridization and immunohistochemical analysis. Br J Cancer. DOI: 10.1038/sj.bjc.6601703
74. Cossu G., Messerer M., Parker F., Levivier M., Daniel R.T. 2016. Meningiomas' Management: An Update of the Literature. Neurooncology-Newer Developments DOI:10.5772/62929

75. Goldbrunner R., Minniti G., Preusser M., Jenkinson M. D., Sallabanda K., Houdart E., Deimling A. 2016. EANO guidelines for the diagnosis and treatment of meningiomas. DOI: 10.1016/S1470-2045(16)30321-7
76. Saraf S., Mccarthy B.J., Villano J.L. 2011. Update on Meningiomas. The Oncologist 2011;16:1604 –1613. DOI: 10.1634/theoncologist.2011-0193
77. Dahlan MS. 2017. Pintu Gerbang Memahami Epidemiologi, Biostatistik, dan Metode Penelitian. Edisi 2. Epidemiologi Indonesia; Jakarta Timur
78. Kinra P, Malik A. 2020. Ki67: Are we counting it right? Indian J Pathol Microbiol. DOI: 10.4103/IJPM.IJPM_770_19
79. Notoatmodjo S. 2010. Metodologi Penelitian Kesehatan. Rineka Cipta; Jakarta
80. Yusriany R et al. 2019. Relationship between mitotic index and Ki67 expression in meningioma. International Journal of Research in Medical Sciences. DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20193944
81. Backer-Grøndahl T, Moen BH, Torp SH. The histopathological spectrum of human meningiomas. Int J clin exp pathol. 2012;5(3):231-42
82. Ildan F, Erman T, Göçer Al, Tuna M, Bağdatoğlu H, Cetinalp E, et al. Predicting the probability of meningioma recurrence in the preoperative and early postoperative period: A multivariate analysis in the midterm follow-up. Skull Base 2007;17:157-71
83. Kasuya H, Kubo O, Tanaka M, Amano K, Kato K, Hori T. Clinical and radiological features related to the growth potential of meningioma. Neurosurg Rev 2006;29:293-7
84. Monappa V., Solanke G., Kudva R. 2020. Histopathological Spectrum of Meningiomas with Emphasis on Prognostic Role of Ki67 Labelling Index. Iranian Journal of Pathology. DOI: 10.30699/ijp.2020.107195.2119
85. Roser F., Samii M., Ostertag H., Bellinzona M. 2004. The Ki-67 proliferation antigen in meningiomas. Experience in 600 cases. Acta Neurochir (Wien). DOI 10.1007/s00701-003-0173-4
86. Haddad AF. et.al. 2020. WHO Grade I Meningioma Recurrence: Identifying High Risk Patients Using Histopathological Features and the MIB-1 Index. Front. Oncol. 10:1522. doi: 10.3389/fonc.2020.01522
87. Chiba K. et.al. 2021. Atypical Histological Features as Risk Factors for Recurrence in Newly Diagnosed WHO Grade I Meningioma. Neurol Med Chir (Tokyo) 61, 647–651. doi: 10.2176/nmc.oa.2021-0153

88. Abry E. et.al. 2010. The significance of Ki-67/MIB-1 Labeling Index in Human Meningiomas: A Literature Study. Pathology – Research and Practice 206. doi:10.1016/j.prp.2010.09.002